A study assessing the combination of RMC-4630 with osimertinib for solid tumors
Latest Information Update: 05 Mar 2021
At a glance
- Drugs Osimertinib (Primary) ; Vociprotafib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors REVOLUTION Medicines
- 02 Mar 2021 According to a REVOLUTION Medicines media release, the company expects initial tolerability and pharmacokinetic (PK) data from this combination in the second half of 2021.
- 12 Nov 2020 Status changed from planning to recruiting, according to a REVOLUTION Medicines media release.
- 17 Aug 2020 New trial record